February 23, 2023JAMA OncologyOpen Access

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval

View Full Paper

Ask AI

Bookmark

Abstract

This cross-sectional study evaluates patient exposure to oncology drugs withdrawn from the US Food and Drug Administration (FDA) Accelerated Approval program.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Parikh et al. (2023) studied this question.

synapsesocial.com/papers/6a22d7e7c20dee76e681dda7 https://doi.org/10.1001/jamaoncol.2022.7770

View Full Paper

Ask AI

Bookmark

Abstract

This cross-sectional study evaluates patient exposure to oncology drugs withdrawn from the US Food and Drug Administration (FDA) Accelerated Approval program.

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval

Abstract

Discussion

Cite This Study

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval

Abstract

Discussion

Cite This Study

Keep reading

Keep reading